Trial reportClinical pharmacology and therapeutics2022
OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005.
Trial report in Clinical pharmacology and therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- In vivo human keyhole limpet hemocyanin challenge in early phase drug development: A systematic review.Clinical and translational science · 2023Pooled it
- Population Pharmacokinetic and Pharmacodynamic Modeling for the Prediction of the Extended Amlitelimab Phase 3 Dosing Regimen in Atopic Dermatitis.CPT: pharmacometrics & systems pharmacology · 2025Trial
- Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimab.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Trial
- Profiling a Neo-Antigen-Driven Immune Response in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Study of the KLH Challenge Model.Clinical pharmacology and therapeutics · 2025Trial
- Impact of oral administration of single strainFrontiers in immunology · 2022Trial
- Atopic Dermatitis: New Targets and Emerging Systemic Therapies.American journal of clinical dermatology · 2026Review
- Decoding TNF receptor superfamily control of CD4Cell communication and signaling : CCS · 2026Review
- The Role of OX40 Pathway Inhibition as a New Therapeutic Strategy for Atopic Dermatitis.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Heterogeneity in Atopic Dermatitis: Ethnic, Anatomical Site, and Age-related Variations.Clinical reviews in allergy & immunology · 2026Review
- A Post Hoc Analysis of Atopic Dermatitis of the Head and Neck and Other Body Regions from the Amlitelimab STREAM-AD Phase 2b Study.Dermatology and therapy · 2026Article
- Combination antagonism of TNF superfamily signaling for T cell immunosuppression.Frontiers in immunology · 2026Article
- In Vitro Evidence Demonstrating the Nondepleting Mechanism of Action of Amlitelimab, an OX40 Ligand Monoclonal Antibody.Acta dermato-venereologica · 2025Article
- Combined TNF-α and OX40L targeting as a new treatment option for hidradenitis suppurativa.The journal of allergy and clinical immunology. Global · 2025Article
- Anti-Inflammatory Therapies for Atopic Dermatitis: A New Era in Targeted Treatment.Journal of clinical medicine · 2025Review
- Tolerogenic Therapies in Cardiac Transplantation.International journal of molecular sciences · 2025Review
- T cell-B cell interactions in human autoimmune diseases.Current opinion in immunology · 2025Review
- OX40/OX40L as a Therapeutic Target in Atopic Dermatitis: A Scoping Review.Biologics : targets & therapy · 2025Review
- A Narrative Review of the OX40-OX40L Pathway as a Potential Therapeutic Target in Atopic Dermatitis: Focus on Rocatinlimab and Amlitelimab.Dermatology and therapy · 2024Review
- Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer.Nature reviews. Drug discovery · 2024Review
- Anti-OX40 Biological Therapies in the Treatment of Atopic Dermatitis: A Comprehensive Review.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The safety, tolerability, immunogenicity, and pharmacokinetic (PK) profile of an anti-OX40L monoclonal antibody (KY1005, currently amlitelimab) were evaluated. Pharmacodynamic (PD) effects were explored using keyhole limpet hemocyanin (KLH) and tetanus toxoid (TT) immunizations. Sixty-four healthy male subjects (26.5 ± 6.0 years) were randomized to single doses of 0.006, 0.018, or 0.05 mg/kg, or multiple doses of 0.15, 0.45, 1.35, 4, or 12 mg/kg KY1005, or placebo (6:2). Serum KY1005 concentrations were measured. Antibody responses upon KLH and TT immunizations and skin response upon intradermal KLH administration were performed. PD data were analyzed using repeated measures analysis of covariances (ANCOVAs) and post hoc exposure-response modeling. No serious adverse events occurred and all adverse events were temporary and of mild or moderate severity. A nonlinear increase in mean serum KY1005 concentrations was observed (median time to maximum concentration (T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.